Document:

EX-10.20

 Exhibit 10.20 

December 30, 2014 
 Dr. Ari Kellen 

Dear Ari: 
 This letter outlines the details of your employment
with Valeant Pharmaceuticals International, Inc. or its applicable subsidiary (the “Company”), and your Company assignment. 
  

	 	•	 	Title: Executive Vice President. You will report to the Chief Executive Officer, who will determine your specific title and duties. 

 

	 	•	 	Office Location: Your principal place of employment will be in New Jersey. 

  

	 	•	 	Base Salary: Your base salary will be $62,500 per month ($750,000 annualized). 

  

	 	•	 	One-time Performance Bonus. The Company agreed to pay you a one-time performance bonus between zero and $8,000,000, based on your achievements with respect to the integration and restructuring of the
Bausch + Lomb business, as such achievement is assessed by the Chief Executive Officer and which amount is to be paid no later than January 15, 2015, subject to your continued employment on the payment date. 

 

	 	•	 	Annual Incentive: You will be eligible to participate in the Company’s management bonus plan beginning with the 2014 calendar year. Your target bonus will be 120% of your base salary, with the
potential of up to 240% of your base salary. This plan, and therefore your participation, is subject to change at the discretion of the Board of Directors. Bonuses are payable at the time the other management bonuses are paid. To be eligible for any
bonus payment, you must be employed by the Company, and you must not have given or received notice of the termination of your employment, on the day on which the applicable bonus is paid to other members of the Company management. You will not be
eligible for an annual incentive bonus with respect to any portion of the 2013 calendar year. 

  

	 	•	 	Equity Awards: The Company’s Talent and Compensation Committee of the Company’s Board of Directors (the “Committee”) has approved grants of a target number of 150,000 Performance-based
Restricted Share Units (each, a “PSU”). 

 75,000 of the PSUs shall vest between 0-300%, based on meeting certain
Company performance criteria described below, as measured approximately three years from the grant date and 75,000 of the PSUs shall vest between 0-300%, based on meeting certain Company performance criteria described below, as measured
approximately five years from the grant date. The triggers for 1x, 2x and 3x vesting shall be based on attaining a 

 December 30, 2014 

Mr. Ari Kellen 
 Page 2 of 10 

 

 
10%, 20% and 30% 3-year or 5-year, as applicable, compound total shareholder return, respectively, with measurements governed by the award agreement (which shall contain terms consistent with the
terms customarily provided to other similarly situated executives of the Company, with such modifications to reflect that the primary performance measurement period is 3 years or 5 years, as applicable, and such other terms as approved by the
Committee). 
  

	 	•	 	Share Ownership Commitment. You also agree to comply with any share ownership requirements adopted by the Company applicable to you, which shall be on the same terms as similarly situated executives of the
Company. 

  

	 	•	 	Matching Grants for Share Purchases. In connection with such share ownership, you shall also be eligible to receive matching share units under the Company’s matching share unit program.
Notwithstanding anything in such program to the contrary, you shall receive a grant of one matching share unit for each common share of the Company purchased, up to $5,000,000 in purchases. Each such matching share unit shall vest in equal annual
portions over the 5-year period following grant and shall have such other terms consistent with the terms customarily provided to similarly situated executives of the Company. 

 

	 	•	 	Good Reason. You may terminate your employment for Good Reason (as defined below) by delivering to the Company a Notice of Termination (as defined below) not less than thirty (30) days prior to the
termination of your employment for Good Reason. The Company shall have the option of terminating your duties and responsibilities prior to the expiration of such thirty-day notice period, subject to the payment by the Company of the compensation and
benefits provided in this letter, as may be applicable. For purposes of this letter, “Good Reason” shall mean the occurrence of any of the events or conditions described in clauses (i) through (iii) immediately below which are
not cured by the Company (if susceptible to cure by the Company) within thirty (30) days after the Company has received a “Notice of Termination.” “Notice of Termination” means a written notice provided by you within ninety
(90) days of the initial existence of the event or condition constituting Good Reason specifying the particular events or conditions which constitute Good Reason and the specific cure requested by you. 

 

	 	(i)	Diminution of Responsibility. (A) any material reduction in your duties or responsibilities as in effect immediately prior thereto, or (B) removal of you from the position of Executive Vice President . For the
avoidance of doubt, the term “Diminution of Responsibility” shall not include (Y) any such removal resulting from a promotion, your death or Disability, the termination of your employment for Cause, or your termination of your
employment other than for Good Reason, (Z) the reduction of or change in any particular duties or responsibilities provided you are given other duties or responsibilities such that your overall duties and responsibilities remain substantially
comparable to your overall duties and responsibilities prior to the reduction or change; 

 December 30, 2014 

Mr. Ari Kellen 
 Page 3 of 10 

 

	 	(ii)	Compensation Reduction. Any reduction in your base salary or target bonus opportunity which is not comparable to reductions in the base salary or target bonus opportunity of other similarly-situated senior executives at
the Company; or 

  

	 	(iii)	Company Breach. Any other material breach by the Company of any material provision of this letter. 

  

	 	•	 	Change in Control. For purposes of this letter, a “Change in Control” shall mean any of the following events: 

 

	 	(i)	the acquisition (other than from the Company), by any person (as such term is defined in Section 13(c) or 14(d) of the Securities Exchange Act of 1934, as amended (the “1934 Act”)) of beneficial ownership
(within the meaning of Rule 13d-3 promulgated under the 1934 Act) of fifty percent (50%) or more of the combined voting power of the Company’s then outstanding voting securities; 

 

	 	(ii)	the individuals who, as of the date hereof, are members of the Board (the “Incumbent Board”), cease for any reason to constitute at least a majority of the Board, unless the election, or nomination for
election by the Company’s stockholders, of any new director was approved by a vote of at least a majority of the Incumbent Board, and such new director shall, for purposes of this letter, be considered as a member of the Incumbent Board; or

  

	 	(iii)	the closing of: 

  

	 	1.	a merger or consolidation involving the Company if the stockholders of the Company, immediately before such merger or consolidation, do not, as a result of such merger or consolidation, own, directly or indirectly, more
than fifty percent (50%) of the combined voting power of the then outstanding voting securities of the corporation resulting from such merger or consolidation in substantially the same proportion as their ownership of the combined voting power
of the voting securities of the Company outstanding immediately before such merger or consolidation; or 

  

	 	2.	a complete liquidation or dissolution of the Company or an agreement for the sale or other disposition of all or substantially all of the assets of the Company. 

 December 30, 2014 

Mr. Ari Kellen 
 Page 4 of 10 

 

 Notwithstanding the foregoing, a Change in Control shall not be deemed to occur pursuant to
this letter agreement, solely because fifty percent (50%) or more of the combined voting power of the Company’s then outstanding securities is acquired by (i) a trustee or other fiduciary holding securities under one or more employee
benefit plans maintained by the Company or any of its subsidiaries or (ii) any corporation which, immediately prior to such acquisition, is owned directly or indirectly by the stockholders of the Company in the same proportion as their
ownership of stock in the Company immediately prior to such acquisition. 
  

	 	•	 	Disability. The Company may terminate your employment, on written notice to you after having established your Disability and while you remain Disabled, subject to the payment by the Company to you of the
applicable compensation and benefits provided pursuant to this letter agreement. For purposes of this letter agreement, “Disability” shall have the meaning assigned to such term in the 2011 Omnibus Incentive Plan. 

 

	 	•	 	Cause. The Company may terminate your employment for “Cause”, subject to the payment by the Company to you of the applicable compensation and benefits provided in this letter agreement.
“Cause” shall mean, for purposes of this letter, “cause” as defined by applicable common law and (1) conviction of any felony or indictable offense (other than one related to a vehicular offense) or other criminal act
involving fraud; (2) willful misconduct that results in a material economic detriment to the Company; (3) material violation of Company policies and directives, which is not cured after written notice and a reasonable opportunity for cure;
(4) continued refusal by you to perform your duties after written notice identifying the deficiencies and a reasonable opportunity for cure; or (5) a material violation by you of any material covenants to the Company. No action or inaction
shall be, or be deemed to be, willful if not demonstrably willful and if taken or not taken by you in good faith and with the understanding that such action or inaction was not adverse to the best interests of the Company. Reference in this
paragraph to the Company shall also include direct and indirect subsidiaries of the Company, and materiality shall be measured based on the action or inaction and the impact upon the Company taken as a whole. The Company may suspend you, with pay,
upon your indictment for the commission of a felony or indictable offense as described under clause (1) above. Such suspension may remain effective until such time as the indictment is either dismissed or a verdict of not guilty has been
entered. 

  

	 	•	 	 Employee and Executive Benefits. You will be eligible to participate in the employee benefit plans and programs generally made available
to similarly situated employees of the Company on the terms and conditions applicable generally to all employees. In addition, the Company shall reimburse you for incremental taxes incurred by you outside of the United States because of any
services you provide to the Company outside of the United States or any business that the Company conducts outside of the United States, if such incremental amount during any tax year exceeds 1% or more of your average base salary for such
tax year. You 

 December 30, 2014 

Mr. Ari Kellen 
 Page 5 of 10 

 

 
shall be required to participate in any tax equalization program the Company may have in effect from time to time in order to qualify for the benefit described in the
preceding sentence. 
  

	 	•	 	Conditions to Reimbursement. The following provisions shall be in effect for any reimbursements (and in-kind benefits) to which you otherwise may become entitled under this letter, in order to assure that
such reimbursements (and in-kind benefits) do not create a deferred compensation arrangement subject to Section 409A of the Internal Revenue Code (“Section 409A”): 

 

	 	(i)	The amount of reimbursements (or in-kind benefits) to which you may become entitled in any one calendar year shall not affect the amount of expenses eligible for reimbursement (or in-kind benefits) hereunder in any
other calendar year. 

  

	 	(ii)	Each reimbursement to which you become entitled shall be made by the Company as soon as administratively practicable following your submission of the supporting documentation, but in no event later than the close of
business of the calendar year following the calendar year in which the reimbursable expense is incurred. 

  

	 	(iii)	Your right to reimbursement (or in-kind benefits) cannot be liquidated or exchanged for any other benefit or payment. 

  

	 	•	 	At-Will Employment. Your employment with the Company is “at will”. This means that you or the Company have the option to terminate your employment at any time, with or without advance notice, and
with or without Cause or with or without Good Reason. This letter of employment does not constitute an express or implied agreement of continuing or long term employment. The at will nature of your employment can be altered only by a written
agreement specifying the altered status of your employment. Such written agreement must be signed by both you and the Chief Executive Officer. 

  

	 	•	 	Severance Benefits. Notwithstanding the immediately preceding bullet paragraph, if your employment is terminated by the Company without Cause or by you for Good Reason, the Company shall have the following
obligations: 

  

	 	(i)	The Company will pay you an amount equal to the sum of (A) your annual salary as of the Termination Date, plus (B) your annual target bonus as of the Termination Date, provided that, if your termination occurs
either in contemplation of a Change in Control or at any time within twelve (12) months following a Change in Control, the Company shall instead pay you an amount equal to two times the sum of (A) your annual salary as of the Termination
Date, plus (B) your annual target bonus as of the Termination Date. The “Termination Date” shall be the date specified as the effective date of the termination of your employment in any notice of termination of employment provided by
the Company to you or accepted by the Company in the event of your giving notice of the termination of your employment. 

 December 30, 2014 

Mr. Ari Kellen 
 Page 6 of 10 

 

	 	(ii)	The Company will pay you any accrued but unpaid salary or vacation pay and any deferred compensation. In addition, the Company will pay you any bonus earned but unpaid in respect of any fiscal year preceding the
Termination Date. The Company will also pay you a bonus in respect of the fiscal year in which the Termination Date occurs, as though you had continued in employment until the payment of bonuses by the Company to its executives for such fiscal year,
in an amount equal to the product of (A) the lesser of (x) the bonus that you would have been entitled to receive based on actual achievement against the stated performance objectives or (y) the bonus that you would have been entitled
to receive assuming that the applicable performance objectives for such fiscal year were achieved at “target”, and (B) a fraction (i) the numerator of which is the number of days in such fiscal year through Termination Date and
(ii) the denominator of which is 365; provided that, if your termination occurs either in contemplation of a Change in Control or at any time within twelve (12) months following a Change in Control, then in the foregoing calculation the
amount under (A) shall be equal to (y). Any bonus payable to you under this bullet shall be paid in no event later than March 15 of the calendar year following the calendar year in which the Termination Date occurs. 

 

	 	(iii)	The Company will provide you with continued coverage under any health, medical, dental or vision program or policy in which you were eligible to participate at the time of your employment termination for 12 months
following such termination on terms no less favorable to you and your dependents (including with respect to payment for the costs thereof) than those in effect immediately prior to such termination. 

 

	 	(iv)	The Company shall provide outplacement services through one or more outside firms of your choosing up to an aggregate of $20,000, which services shall extend until the earlier of (i) 12 months following the
Termination Date or (ii) the date that you secure full time employment. 

 Notwithstanding anything herein to the
contrary, the Company shall have no obligation to pay or provide any of the severance benefits referenced or set forth in this letter and shall have no obligations to you in respect of the termination of your employment save and except for
obligations that are expressly established by applicable employment standards legislation unless you execute and deliver, within 45 days of the date of your termination, and do not revoke, a general release in form satisfactory to the Company and
any revocation period set forth in the release has lapsed. Subject to compliance with Section 409A, the Company shall pay all cash severance benefits due within 10 business days following the satisfaction of all of the conditions set forth in
the preceding sentence. You shall not be required to mitigate the amount of any severance payment provided for under this letter by seeking other employment or otherwise and no such payment shall be offset or reduced by the amount of any
compensation or benefits provided to you in any subsequent employment. 

 December 30, 2014 

Mr. Ari Kellen 
 Page 7 of 10 

 

 Notwithstanding anything herein to the contrary, in no event shall the timing of your
execution of the general release, directly or indirectly, result in you designating the calendar year of payment, and if a payment that is subject to execution of the general release could be made in more than one taxable year, payment shall be made
in the later taxable year. 
 It is understood that, during your employment by the Company, you will not engage in any activities that
constitute a conflict of interest with the interests of the Company, as outlined in the Company’s conflict of interest policies for employees and executives in effect from time to time. 

 

	 	•	 	Covenant Not to Solicit. To protect the confidential information and other trade secrets of the Company and its affiliates, you agree, during your employment with the Company or any of its affiliates and
for a period of twelve (12) months after your cessation of employment with the Company or any of its affiliates, not to solicit, attempt to solicit, or participate in or assist in any way in the solicitation or attempted solicitation of any
employees or independent contractors of the Company or any of its affiliates. For purposes of this covenant, “solicit” or “solicitation” means directly or indirectly influencing or attempting to influence employees of the Company
or any of its affiliates to become employed with any other person, partnership, firm, corporation or other entity. You agree that the covenants contained in this paragraph are reasonable and necessary to protect the confidential information and
other trade secrets of the Company and its affiliates, provided, that solicitation through general advertising or the provision of references shall not constitute a breach of such obligations. For purposes of this paragraph, an “affiliate”
shall mean any direct or indirect subsidiary of the Company or any joint venture or collaboration in which any such entity or the Company participates. 

  

	 	•	 	 Remedies for Breach of Obligations Under the Covenants Not to Solicit Above. It is the intent and desire of you and the Company (and its
affiliates) that the restrictive provisions in the paragraph captioned “Covenant Not to Solicit” above be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is
sought. If any particular provision in such paragraph shall be determined to be invalid or unenforceable, such covenant shall be amended, without any action on the part of either party hereto, to delete therefrom the portion so determined to be
invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made. Your obligations under the two preceding paragraphs shall survive the termination
of your employment with or any other employment arrangement with the Company or any of its affiliates. You acknowledge that the Company or its affiliates will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if
you breach your obligations under the paragraph captioned “Covenant Not to Solicit” above. Accordingly, you agree that the Company and its affiliates will be entitled, in addition to any other available remedies, to obtain

 December 30, 2014 

Mr. Ari Kellen 
 Page 8 of 10 

 

	 	 
injunctive relief against any breach or prospective breach by you of your obligations under either such paragraph in any Federal or state court sitting in the State of New Jersey, or, at the
Company’s (or its affiliate’s) election, in any other state or jurisdiction in which you maintain your principal residence or your principal place of business. You agree that the Company or its affiliates may seek the remedies described in
the preceding sentence notwithstanding any arbitration or mediation agreement that you may enter into with the Company or any of its affiliates. You hereby submit to the non-exclusive jurisdiction of all those courts for the purposes of any actions
or proceedings instituted by the Company or its affiliates to obtain that injunctive relief, and you agree that process in any or all of those actions or proceedings may be served by registered mail, addressed to the last address provided by you to
the Company or its affiliates, or in any other manner authorized by law. 

  

	 	•	 	Indemnification. You shall be indemnified by the Company as provided in its articles or, if applicable, pursuant to an indemnification agreement with the Company if such agreements are provided to
similarly situated executives. 

  

	 	•	 	Section 409A. The parties intend for the payments and benefits under this letter to be exempt from Section 409A or, if not so exempt, to be paid or provided in a manner which complies with the
requirements of such section, and intend that this letter shall be construed and administered in accordance with such intention. Any payments that qualify for the “short-term deferral” exception or another exception under Section 409A
shall be paid under the applicable exception. For purposes of the limitations on nonqualified deferred compensation under Section 409A, each payment of compensation under this letter shall be treated as a separate payment of compensation.
Notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be
provided pursuant to this letter during the six-month period immediately following your separation from service shall instead be paid on the first business day after the date that is six months following your Termination Date (or death, if earlier),
with interest from the date such amounts would otherwise have been paid at the short-term applicable federal rate, compounded semi-annually, as determined under Section 1274 of the Internal Revenue Code of 1986, as amended, for the month in
which payment would have been made but for the delay in payment required to avoid the imposition of an additional rate of tax on you under Section 409A. 

  

	 	•	 	Withholding Taxes. All payments to you or your beneficiary under this letter agreement shall be subject to withholding on account of federal, state and local taxes as required by law. 

You acknowledge that you have, reviewed, agreed, signed and returned the Company’s customary on-boarding documentation. 

 December 30, 2014 

Mr. Ari Kellen 
 Page 9 of 10 

 

 Policies of the Company will govern any other matter not specifically covered by this letter. 

Except as specifically described in the following sentence, the terms of this letter constitute the entire agreement between the Company and you with respect
to the subject matter hereof, superseding all prior agreements and negotiations This letter is governed by the laws of the State of New Jersey. All currency amounts set forth in the letter agreement refer to U.S. dollars. 

This letter and the documents referenced herein are the full, complete and exclusive agreement between you and the Company regarding all of the subjects
covered by this letter, and supersede in their entirety any other written or verbal agreement between you and the Company, including, without limitation, any previous letters or agreements, whether written or verbal, relating to any offer or other
terms of employment. 

 December 30, 2014 

Mr. Ari Kellen 
 Page 10 of 10 

 

 As confirmation of acceptance of this employment letter, please sign this letter indicating your agreement
and acceptance of the terms and conditions of employment. In addition, please mail the original signed employment letter in the envelope provided. A duplicate copy of this employment letter is included for your records. 

 

			
	Sincerely,
	
	Valeant Pharmaceuticals International, Inc.
		
	By:		     /s/ J. Michael Pearson

			    J. Michael Pearson
			    Chief Executive Officer
		
			     /s/ Ari Kellen

			    Ari KellenEX-10.21

 Exhibit 10.21 

April 2, 2012 
 Pavel Mirovsky 

Dear Pavel: 
 This letter outlines the details of your
employment with PharmaSwiss AG, having its registered office at: Baarerstrasse 94, 6300 Zug, Switzerland, Identification Number: CH-170.3.023.567-7 (the “Company), the employing entity and subsidiary of Valeant Pharmaceutical International,
Inc., having its registered office at: Baarerstrasse 94, 6300 Zug, Switzerland, Identification Number: CH-170.3.023 .567-7 (“VPII”). 
  

	 	•	 	Title: General Manager and President, Valeant Europe reporting to J. Michael Pearson. 

  

	 	•	 	Location: Your principal office location will be Prague, Czech Republic. You agree to make, from time to time, business trips for the Company’s benefit, either in the Czech Republic or abroad, under
the Company’s instructions and operational needs, in the extent of up to 250 days per calendar year. 

  

	 	•	 	Commencement of Work: You are already working for the Company. This agreement is therefore effective as of 1 January 2012. 

 

	 	•	 	Time Worked and Vacation: Subject to mandatory laws, the following applies to working hours and vacation. You agree to exercise your best efforts to successfully and carefully accomplish the duties
assigned to you by the Company and further agree that you shall devote at least 40 hours per week to service on behalf of the Company. You agree to perform overtime work if necessary. It is understood that no extra compensation shall be paid for the
performance of overtime work or work performed on days or during hours of the day which may be considered outside customary working hours. You shall be entitled to 30 days of paid vacation per calendar year. 

You agree to devote your efforts exclusively to the Company in furtherance of the Company’s interests. Any engagement in additional
occupations for remuneration or any participation in any kind of enterprise requires the written consent of the Company. This shall not apply to the usual acquisition of shares of other stocks or other shares for investment purposes. Membership in
the board of directors or supervisory board of other companies shall also require the written approval of the Company. 
  

	 	•	 	Base Salary: Your annual gross base salary will be €360,000 (or €30,000 per month). 

  

	 	•	 	Annual Incentive: You will be eligible to participate in the VPII management bonus plan. Beginning with the 2012 calendar year your target bonus will be 50%, with the potential of 100%, of your annual base
salary. This plan, and therefore your participation, is subject to change at the discretion of the Board of Directors of VPII. Bonuses are payable at the time the VPII management bonuses are paid, generally in March each year. To be eligible for any
bonus payment, you must be employed by the Company, and not have given or received notice of the termination of your employment, on the day on which the applicable bonus is paid to VPII members of management. It is in the unfettered discretion of
the Board of Directors of VPII to change the bonus plan, and you have no claim against the Company under this Clause or the management bonus plan. 

 April 2, 2012 

 Page
 2
 of 4 
  

	 	•	 	Equity Awards: The Company will recommend to VPII’s Talent and Compensation Committee of the Board the following equity awards: 

 

	 	•	 	10,000 Performance Stock Units (PSUs) with between 0 and 300% vesting as measured on the date that is three years from the grant date, based on meeting certain company performance criteria. 

 

	 	•	 	20,000 Stock Options with 25% vesting on each anniversary of the grant date. The stock options will have a ten year term. 

  

	 	•	 	The awards are contingent upon your acceptance of the offer and the terms of the awards and approval of the Talent and Compensation Committee. The terms and conditions of these awards will be detailed in each award
agreement and/or plan document. 

  

	 	•	 	It is in the unfettered discretion of the Talent and Compensation Committee to approve the awards or not, and you have no claim against your employing entity under this Clause or the awards. 

 

	 	•	 	Further payments. Unless otherwise expressly agreed upon in writing, the payment of any other gratuities, profit shares, premiums or other extra payments shall be on a voluntary basis, subject to the provision
that even repeated payments without the reservation of voluntarity shall not create any legal claim for you, either in respect to their cause or their amount, either for the past or for the future. 

 

	 	•	 	Notice of Termination. Your employment may be terminated at any time giving one month notice prior written notice as per the end of each month. This offer of employment does not constitute an express or
implied agreement of continuing or long term employment with the Company, the Company or any affiliate of the Company. This clause can be altered only by a written agreement. 

 

	 	•	 	Severance Benefits. Notwithstanding the immediately preceding bullet paragraph, if your employment is terminated by the Company, the Company shall be obligated to pay you only such severance as is required
per applicable law unless you are terminated as a direct result of a change in control as discussed below. You agree and acknowledge that you are not entitled to receive any other severance payments or benefits from the Company or any of its
affiliates. 

  

	 	•	 	Severance Benefits related to a Change in Control. If your employment is terminated by the Company within 12 months following a “Change in Control”, the Company shall be obligated to pay you
the lesser of (a) the amount equal to your then current base salary through the period ending on 31 March 2015 or (b) an amount equal to 12 months of your then current base salary. For purposes of this letter, the
term “Change in Control” means the acquisition of more than 50% of the equity interest or assets of Valeant Pharmaceuticals International, Inc. by an unaffiliated third party. 

It is understood that, during your employment by the Company or any of its affiliates, you will not engage in any activities that constitute a
conflict of interest with the interests of the Company or any of its affiliates, as outlined in VPII’s conflict of interest policies for employees and executives in effect from time to time. 

 

	 	•	 	Covenant Not to Solicit. To protect the confidential information and other trade secrets of the Company and its affiliates, you agree, during your employment with the Company or any of its affiliates and
for a period of one year (12) months following the effective date of this employment agreement, the Employee will not, directly or indirectly, solicit for employment or hire any officer or employee of the Company or any of its subsidiaries that
the Employee was in regular contact with, or had an access to information with respect to in the Employee’s ordinary course of work, provided that the foregoing shall not preclude the Employee from hiring any such officer or employee who
(i) has had his or her employment terminated by the Company prior to commencement of employment discussions between the Employee and such officer or employee or (ii) contacts the Employee in response to employment advertisement in
generally circulated media. 

 April 2, 2012 

 Page
 3
 of 4 
  

	 	•	 	Remedies for Breach of Obligations Under the Covenants Not to Solicit Above. It is the intent and desire of you and the Company (and its affiliates) that the restrictive provisions in the paragraph
captioned “Covenant Not to Solicit” above be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought. If any particular provision in such paragraph shall
be determined to be invalid or unenforceable, such covenant shall be amended, without any action on the part of either party hereto, to delete therefrom the portion so determined to be invalid or unenforceable, such deletion to apply only with
respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made. Your obligations under the two preceding paragraphs shall survive the termination of your employment with or any other employment
arrangement with the Company or any of its affiliates. You acknowledge that the Company or its affiliates will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if you breach your obligations under the paragraph
captioned “Covenant Not to Solicit” above. Accordingly, you agree that the Company and its affiliates will be entitled, in addition to any other available remedies, to obtain injunctive relief against any breach or prospective breach by
you of your obligations under either such paragraph in any Federal or state court sitting in the State of New Jersey, or, at the Company’s (or its affiliate’s) election, in any other state or jurisdiction in which you maintain your
principal residence or your principal place of business. You agree that the Company or its affiliates may seek the remedies described in the preceding sentence notwithstanding any arbitration or mediation agreement that you may enter into with the
Company or any of its affiliates. You hereby submit to the non-exclusive jurisdiction of all those courts for the purposes of any actions or proceedings instituted by the Company or its affiliates to obtain that injunctive relief, and you agree that
process in any or all of those actions or proceedings may be served by registered mail, addressed to the last address provided by you to the Company or its affiliates, or in any other manner authorized by law. 

 

	 	•	 	Data Protection: With the execution of this letter, you consent that the Company may store, transfer, change and delete all personal data in connection with your employment relationship. You acknowledge
that personal data may be transferred to companies outside Switzerland and the Czech Republic affiliated with the Company. 

  

	 	•	 	Withholding Taxes and Contributions. All payments to you or your beneficiary under this letter agreement shall be subject to withholding on account of federal, state and local taxes and social security and
health insurance contributions as required by law. 

  

	 	•	 	Applicable Law. You agree that your employment is subject to Swiss law and that the Courts in Zug have exclusive jurisdiction. 

It is understood that you are required to have read, reviewed, agreed, signed and returned to the Company the Company’s Standards of Business Conduct,
Insider Trading Policy, Blackout Policy and Global Anti-Bribery Policy, and by signing below you acknowledge your requirement to comply with such documents and policies at all times during your employment with the Company or any of its affiliates.

 Policies of the Company will govern any other matter not specifically covered by this letter. 

As confirmation of acceptance of this employment offer, please sign this letter indicating your agreement and acceptance of the terms and conditions of
employment. In addition, please mail the original signed offer letter in the envelope provided. A duplicate copy of this offer letter is included for your records. 

 April 2, 2012 

 Page
 4
 of 4 

 
			
	Sincerely,
		
	By:		 /s/ J. Michael Pearson

			J. Michael Pearson
			Chief Executive Officer
			(for and on behalf of PharmaSwiss SA)
		
			 /s/ Pavel Mirovsky

			Pavel Mirovsky

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]